Article
Oncology
Amir Goldkorn, Catherine Tangen, Melissa Plets, Gareth J. Morrison, Alexander Cunha, Tong Xu, Jacek K. Pinski, Sue A. Ingles, Timothy Triche, Andrea L. Harzstark, Manish Kohli, Gary R. MacVicar, Daniel A. Vaena, Anthony W. Crispino, David J. McConkey, Primo N. Lara, Maha H. A. Hussain, David I. Quinn, Nicholas J. Vogelzang, Ian Murchie Thompson, Neeraj Agarwal
Summary: The CellSearch CTC count can effectively predict the PSA levels within 7 months and progression-free survival within 2 years in mCSPC patients. Patients with undetectable CTCs have a higher chance of achieving favorable treatment outcomes.
CLINICAL CANCER RESEARCH
(2021)
Review
Medicine, Research & Experimental
Qi-Dong Xia, Si-Han Zhang, Na Zeng, Yu-Chao Lu, Bao-Long Qin, Shao-Gang Wang
Summary: Androgen receptor (AR) signaling plays a crucial role in prostate cancer treatment. Traditional approaches are no longer effective in managing the disease progression. Recent studies have shown that novel AR inhibitors can significantly delay disease progression and prolong overall survival in early systemic treatment. However, the increased treatment choices also pose challenges in making treatment decisions.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Endocrinology & Metabolism
Thibault Rossignol, Gilles Gourtaud, Cedric Senechal, Yvane Sadreux, Virginie Roux, Pascal Blanchet, Laurent Brureau
Summary: This study aimed to describe the characteristics and estimate the progression-free survival of men with metastatic hormone-sensitive prostate cancer in an Afro-Caribbean population. Data from 133 men with mHSPC were analyzed, with no significant difference in progression-free survival between the different treatment options. Further studies with larger sample sizes and molecular factors are needed to confirm these results and understand the evolution of prostate cancer in this population.
Article
Medicine, General & Internal
Gerhardt Attard, Laura Murphy, Noel W. Clarke, William Cross, Robert J. Jones, Christopher C. Parker, Silke Gillessen, Adrian Cook, Chris Brawley, Claire L. Amos, Nafisah Atako, Cheryl Pugh, Michelle Buckner, Simon Chowdhury, Zafar Malik, J. Martin Russell, Clare Gilson, Hannah Rush, Jo Bowen, Anna Lydon, Ian Pedley, Joe M. O'Sullivan, Alison Birtle, Joanna Gale, Narayanan Srihari, Carys Thomas, Jacob Tanguay, John Wagstaff, Prantik Das, Emma Gray, Mymoona Alzoueb, Omi Parikh, Angus Robinson, Isabel Syndikus, James Wylie, Anjali Zarkar, George Thalmann, Johann S. de Bono, David P. Dearnaley, Malcolm D. Mason, Duncan Gilbert, Ruth E. Langley, Robin Millman, David Matheson, Matthew R. Sydes, Louise C. Brown, Mahesh K. B. Parmar, Nicholas D. James
Summary: The combination therapy of abiraterone acetate with prednisolone showed significantly higher rates of metastasis-free survival compared with ADT alone in men with high-risk non-metastatic prostate cancer. This combination therapy may be considered a new standard treatment for this patient population.
Article
Oncology
Yujiro Nagata, Takuo Matsukawa, Ikko Tomisaki, Naohiro Fujimoto
Summary: This study investigated the prognostic use of the 3-month PSA level after androgen-deprivation therapy in patients with mHSPC. The results showed that PSA3m can be a useful prognostic biomarker for predicting overall survival in patients with mHSPC. Particularly in elderly patients with low-volume and low-risk mHSPC, the level of PSA3m can help determine whether excessive combination therapy is necessary.
ANTICANCER RESEARCH
(2022)
Article
Oncology
Masaki Shiota, Naoki Terada, Hiroshi Kitamura, Takahiro Kojima, Toshihiro Saito, Akira Yokomizo, Naoki Kohei, Takayuki Goto, Sadafumi Kawamura, Yasuhiro Hashimoto, Atsushi Takahashi, Takahiro Kimura, Ken-ichi Tabata, Ryotaro Tomida, Kohei Hashimoto, Toshihiko Sakurai, Toru Shimazui, Shinichi Sakamoto, Manabu Kamiyama, Nobumichi Tanaka, Koji Mitsuzuka, Takuma Kato, Shintaro Narita, Hiroaki Yasumoto, Shogo Teraoka, Masashi Kato, Takahiro Osawa, Yoshiyuki Nagumo, Hiroaki Matsumoto, Hideki Enokida, Takayuki Sugiyama, Kentaro Kuroiwa, Takahiro Inoue, Mikio Sugimoto, Takashi Mizowaki, Toshiyuki Kamoto, Hiroyuki Nishiyama, Masatoshi Eto
Summary: A novel risk model for survival in patients with metastatic hormone-sensitive prostate cancer was developed and validated in this study. Different adverse factors were identified for low- and high-burden patients, leading to the creation of a risk model tailored to different burdens, which exhibited superior predictive ability compared to previous models.
Article
Oncology
Umang Swami, Ryon P. Graf, Roberto H. Nussenzveig, Virginia Fisher, Hanna Tukachinsky, Alexa B. Schrock, Gerald Li, Jeffrey S. Ross, Nicolas Sayegh, Nishita Tripathi, Vinay Mathew Thomas, Geoffrey R. Oxnard, Emmanuel S. Antonarakis, Neeraj Agarwal
Summary: In patients with de novo metastatic castration-sensitive prostate cancer (dn-mCSPC), SPOP mutations were associated with improved outcomes when treated with androgen receptor axis-targeted therapies (ARAT), but not with docetaxel.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Andrew J. Armstrong, Arun A. Azad, Taro Iguchi, Russell Z. Szmulewitz, Daniel P. Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Antonio Alcaraz, Boris Alekseev, Neal D. Shore, Francisco Gomez-Veiga, Brad Rosbrook, Fabian Zohren, Shunsuke Yamada, Gabriel P. Haas, Arnulf Stenzl
Summary: Clinical Trial Updates provide an opportunity to disseminate additional results from studies that have already reported their primary endpoint. This study demonstrates that enzalutamide plus androgen deprivation therapy significantly prolongs survival in patients with metastatic hormone-sensitive prostate cancer, and continues to improve other secondary endpoints.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Urology & Nephrology
Heng Li, Yucong Zhang, Dong Li, Xin Ma, Kai Xu, Beichen Ding, Hongzhao Li, Zhize Wang, Wei Ouyang, Gongwei Long, Jin Zeng, Haoran Liu, Libin Yan, Yangjun Zhang, Zheng Liu, Wei Guan, Zhiquan Hu, Cong Liu, Jie Wan, Guoping Wang, Xiaoyong Pu, Minghui Zhang, Linlang Guo, Ruihua An, Jiping Qi, Aitao Guo, Zhangqun Ye, Jiumin Liu, Xu Zhang, Hua Xu
Summary: AR-V7 expression in primary cancer tissue is correlated with poor prognosis for mHSPC patients receiving ADT. AR-V7-positive patients had significantly shorter PFS and OS compared to AR-V7-negative patients, indicating that AR-V7 is an independent predictive factor for shorter PFS. Limitations include sample size and follow-up period.
Review
Oncology
Soumyajit Roy, Rashid Sayyid, Fred Saad, Yilun Sun, Katherine Lajkosz, Michael Ong, Zachary Klaassen, Shawn Malone, Daniel E. Spratt, Christopher J. D. Wallis, Scott C. Morgan
Summary: This study compared the efficacy of ADT plus ARAT with the triplet of ADT, ARAT, and docetaxel in mHSPC through a network meta-analysis. The triplet was ranked as the most effective treatment strategy, but it did not show a statistically significant overall survival benefit compared to ADT plus ARAT.
EUROPEAN UROLOGY ONCOLOGY
(2022)
Article
Oncology
Jingsong Zhang, Jill Gallaher, Jessica J. Cunningham, Jung W. Choi, Filip Ionescu, Monica S. Chatwal, Rohit Jain, Youngchul Kim, Liang Wang, Joel S. Brown, Alexander R. Anderson, Robert A. Gatenby
Summary: This study proposes an individualized treatment strategy based on the dynamic response of prostate-specific antigen (PSA) levels in metastatic prostate cancer patients. The use of new hormonal agents combined with on-and-off androgen deprivation therapy (ADT) showed better cancer control and potentially improved survival rates. The feasibility of this adaptive therapy is demonstrated, providing a foundation for future randomized controlled studies in metastatic prostate cancer.
Article
Oncology
Martin R. Stockler, Andrew J. Martin, Ian D. Davis, Haryana M. Dhillon, Stephen D. Begbie, Kim N. Chi, Simon Chowdhury, Xanthi Coskinas, Mark Frydenberg, Wendy E. Hague, Lisa G. Horvath, Anthony M. Joshua, Nicola J. Lawrence, Gavin M. Marx, John McCaffrey, Ray McDermott, Margaret McJannett, Scott A. North, Francis Parnis, Wendy R. Parulekar, David W. Pook, M. Neil Reaume, Shahneen Sandhu, Alvin Tan, Thean Hsiang Tan, Alastair Thomson, Francisco Vera-Badillo, Scott G. Williams, Diana G. Winter, Sonia Yip, Alison Y. Zhang, Robert R. Zielinski, Christopher J. Sweeney
Summary: Enzalutamide improves overall survival in metastatic, hormone-sensitive prostate cancer, but has limited effects on health-related quality of life.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Public, Environmental & Occupational Health
Peng-Fei Zhang, Dan Xie, Qiu Li
Summary: The study evaluated the pharmacoeconomic profile of adding enzalutamide to first-line treatment for mHSPC from the US and Chinese payers' perspectives. Results showed that adding enzalutamide was not cost-effective based on the data from the ENZAMET trial and the current price of enzalutamide.
FRONTIERS IN PUBLIC HEALTH
(2021)
Review
Oncology
Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, Huan He, Noureen Asghar, Rabbia Siddiqi, Hongfang Liu, Parminder Singh, Daniel S. Childs, Praful Ravi, Syed A. Hussain, Mohammad Hassan Murad, Stephen A. Boorjian, Christopher Sweeney, Eliezer M. Van Allen, Alan H. Bryce
Summary: This study aimed to assess the comparative effectiveness of contemporary systemic treatment options for patients with metastatic castration-sensitive prostate cancer (mCSPC) across clinically relevant subgroups. The results suggest that darolutamide (DARO) triplet and abiraterone (AAP) triplet are not associated with improved overall survival (OS) compared to androgen pathway inhibitor (API) doublets in the overall population. However, AAP + D + ADT may improve OS in high-volume disease patients.
Review
Chemistry, Medicinal
Tomoyuki Tatenuma, Hiroshi Miyamoto
Summary: Androgen deprivation therapy is the main treatment for advanced prostate cancer, and relugolix has been developed as an oral alternative. Previous studies have shown comparable efficacy between relugolix and other gonadotropin-releasing hormone antagonists or agonists. This review summarizes the design, development, and therapeutic application of relugolix and discusses its potential as a promising oral alternative to injectable therapy.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2023)
Article
Oncology
Adrianna A. Mendes, Jiayun Lu, Harsimar B. Kaur, Siqun L. Zheng, Jianfeng Xu, Jessica Hicks, Adam B. Weiner, Edward M. Schaeffer, Ashley E. Ross, Steven P. Balk, Mary-Ellen Taplin, Nathan A. Lack, Emirhan Tekoglu, Janielle P. Maynard, Angelo M. De Marzo, Emmanuel S. Antonarakis, Karen S. Sfanos, Corinne E. Joshu, Eugene Shenderov, Tamara L. Lotan
Summary: This study investigates the association of B7-H3 expression with genetic racial ancestry, immune cell composition, and androgen receptor signaling in prostate cancer. The results show that B7-H3 protein expression is inversely correlated with African ancestry and that B7-H3 messenger RNA expression is correlated with tumor T-regulatory cell density. Additionally, hormone therapy is associated with a decrease in B7-H3 protein levels.
Article
Oncology
Mark C. Markowski, Ronald Tutrone, Christopher Pieczonka, K. Gary Barnette, Robert H. Getzenberg, Domingo Rodriguez, Mitchell S. Steiner, Daniel R. Saltzstein, Mario A. Eisenberger, Emmanuel S. Antonarakis
Summary: The clinical trial demonstrated that chronic oral daily dosing of sabizabulin has a favorable safety profile with preliminary antitumor activity.
CLINICAL CANCER RESEARCH
(2022)
Review
Oncology
Arpit Rao, Emmanuel S. Antonarakis
Summary: The approval of rucaparib in the USA in May 2020 marked the introduction of a new class of targeted therapeutics for metastatic castration-resistant prostate cancer. It is important for physicians to understand the role and management of PARP inhibitor therapies in prostate cancer.
EXPERT REVIEW OF ANTICANCER THERAPY
(2022)
Editorial Material
Urology & Nephrology
Editorial Eugene Shenderov, Emmanuel S. Antonarakis
Article
Endocrinology & Metabolism
Christopher T. Su, Emily Nizialek, Jacob E. Berchuck, Panagiotis J. Vlachostergios, Ryan Ashkar, Alexandra Sokolova, Pedro C. Barata, Rahul R. Aggarwal, Rana R. McKay, Neeraj Agarwal, Heather M. McClure, Nellie Nafissi, Alan H. Bryce, Oliver Sartor, Nicolas Sayegh, Heather H. Cheng, Nabil Adra, Cora N. Sternberg, Mary-Ellen Taplin, Marcin Cieslik, Ajjai S. Alva, Emmanuel S. Antonarakis
Summary: PARP inhibitors (PARPi) are standard treatment for mCRPC patients with specific mutations, but response may differ in patients with ATM and BRCA2 mutations. We investigated differences in response to taxanes, which may inform treatment sequencing decisions.
Article
Oncology
Santosh Gupta, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, David M. Nanus, Emmanuel S. Antonarakis, Daniel C. Danila, Russell Z. Szmulewitz, Richard Wenstrup, Andrew J. Armstrong
Summary: PSMA-targeted radioligand therapy has significantly improved clinical outcomes in men with mCRPC. A liquid biopsy characterizing PSMA expression could be useful in guiding optimal therapy.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Emmanuel S. Antonarakis, Sumit K. Subudhi, Christopher M. Pieczonka, Lawrence I. Karsh, David I. Quinn, Jason M. Hafron, Helen M. Wilfehrt, Matthew Harmon, Nadeem A. Sheikh, Neal D. Shore, Daniel P. Petrylak
Summary: The purpose of this study was to investigate the impact of sequential or concurrent administration of androgen receptor-targeting agents (ARTAs) on sipuleucel-T immune response and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC). The results showed that the median OS remained consistent regardless of whether the agents were administered sequentially or concurrently, and sipuleucel-T induced an immunologic prime-boost effect after initial exposure, even when combined with ARTAs.
CLINICAL CANCER RESEARCH
(2023)
Review
Pharmacology & Pharmacy
Adel Mandl, Mark C. Markowski, Michael A. Carducci, Emmanuel S. Antonarakis
Summary: The BET family of proteins are crucial in activating oncogenic networks in different cancers. Therapeutic targeting of BET proteins has shown potential in treating metastatic castration-resistant prostate cancer. However, clinical success has been limited due to treatment-associated toxicities, drug resistance, and a lack of biomarkers.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2023)
Article
Oncology
Michael J. Morris, Glenn Heller, David W. Hillman, Olivia Bobek, Charles Ryan, Emmanuel S. Antonarakis, Alan H. Bryce, Olwen Hahn, Himisha Beltran, Andrew J. Armstrong, Lawrence Schwartz, Lionel D. Lewis, Jan H. Beumer, Brooke Langevin, Eric C. McGary, Paul T. Mehan, Amir Goldkorn, Bruce J. Roth, Han Xiao, Colleen Watt, Mary-Ellen Taplin, Susan Halabi, Eric J. Small
Summary: The purpose of this study was to determine whether the addition of abiraterone acetate and prednisone (AAP) to enzalutamide prolongs overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) in the first-line setting. The results showed that the addition of AAP did not provide a statistically significant benefit in OS compared to enzalutamide treatment alone.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Editorial Material
Oncology
Emmanuel S. Antonarakis, Wassim Abida
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Emmanuel S. Antonarakis, Se Hoon Park, Jeffrey C. Goh, Sang Joon Shin, Jae Lyun Lee, Niven Mehra, Ray McDermott, Nuria Sala-Gonzalez, Peter C. Fong, Richard Greil, Margitta Retz, Juan Pablo Sade, Patricio Yanez, Yi-Hsiu Huang, Stephen D. Begbie, Rustem Airatovich Gafanov, Maria De Santis, Eli Rosenbaum, Michael P. Kolinsky, Felipe Rey, Kun-Yuan Chiu, Guilhem Roubaud, Gero Kramer, Makoto Sumitomo, Francesco Massari, Hiroyoshi Suzuki, Ping Qiu, Jinchun Zhang, Jeri Kim, Christian H. Poehlein, Evan Y. Yu
Summary: This study evaluated the efficacy of pembrolizumab plus olaparib compared to a next-generation hormonal agent (NHA) for heavily pretreated mCRPC patients. The results showed that pembrolizumab plus olaparib did not significantly improve rPFS or OS. The study was stopped for futility and no new safety signals were observed.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Endocrinology & Metabolism
Ali. T. T. Arafa, Leah. R. R. Blader, Karan Ramakrishna, Jeff Engle, Charles. J. J. Ryan, Nicholas. A. A. Zorko, Gautam Jha, Emmanuel. S. S. Antonarakis
Summary: This study evaluated the impact of androgen deprivation therapy (ADT) cessation in patients starting abiraterone for castration-resistant prostate cancer. The results showed that abiraterone alone was associated with comparable clinical outcomes to abiraterone plus ADT. Further prospective studies are needed to assess the impact of abiraterone alone on treatment outcomes and cost savings.
Review
Endocrinology & Metabolism
Ali T. T. Arafa, Aditya Jain, Pavel Skrobanek, Brad Humphrey, Jerry W. W. Froelich, Emmanuel S. S. Antonarakis
Summary: This study assessed the impact of Piflufolastat F-18 (18F-DCFPyL) prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging on clinical practice. The results showed that this technology significantly influenced the initial staging, biochemical recurrence, and restaging of metastatic prostate cancer.
Review
Oncology
Angela Y. Y. Jia, Ana P. Kiess, Qiubai Li, Emmanuel S. Antonarakis
Summary: The discovery of small molecules targeting the extracellular domain of PSMA has advanced diagnostic imaging and precision radiopharmaceutical therapies. This review presents existing data and ongoing clinical evaluations of PSMA-based imaging in the management of prostate cancer. It also discusses clinical studies on PSMA-based radiopharmaceutical therapy and forthcoming trials on early disease states. Multidisciplinary collaboration in trial design and therapeutic administration is crucial for the continued progress of this radiotheranostics field.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Review
Oncology
Sree M. Lanka, Nicholas A. Zorko, Emmanuel S. Antonarakis, Pedro C. Barata
Summary: The development of immune checkpoint inhibitors (ICIs) has revolutionized the treatment landscape of several genitourinary malignancies, but the utility of immunotherapies in prostate cancer has been limited due to its immunologically cold tumor terrain. Pembrolizumab is currently the only approved ICI for metastatic castration resistant prostate cancer (mCRPC) in a select group of patients. Future research is exploring combination approaches with ICIs and other treatments to enhance their efficacy in mCRPC. Additionally, alternative checkpoint inhibitors like B7-H3 hold promise in expanding the treatment options for mCRPC.